A Chinese medicinal wet toxin eliminating decoction for treating eczema and a preparation method thereof

Abstract

The application discloses a kind of traditional Chinese medicine for treating eczema, mainly by first composition and second composition are made, the raw materials of the first composition include: smilax glabra, gangban gui, Chinese potentilla, triaenophora, atractylodes, wind-preventing plant;The raw materials of the second composition include: cortex phellodendri, honeysuckle stem, Chinese alpine, prunus mume, silver radix scophulariae, schisandra chinensis, ramulus mori, portulaca oleracea, licorice, astragalus, capillaria herba.The traditional Chinese medicine for treating eczema of the application, heat-clearing and detoxifying, expelling wind and removing dampness, can better improve the TCM syndrome score, EASI score, the degree of pruritus score, dermatology life quality index (DLQI) score of eczema patient, effectively improve the clinical problems of eczema patient, improve the quality of life.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, and in particular to a Zhuang medicine called Shidu Xiaotang for treating eczema and its preparation method. Background Technology

[0002] Eczema is an inflammatory skin disease characterized by its chronicity and itching. It is caused by multiple factors, including internal and external factors such as genetics, immune dysfunction, and environment. Stress and anxiety can also exacerbate the condition. There are several types of eczema, including acute eczema, subacute eczema, chronic eczema, and special types such as nummular eczema and pompholyx. Eczema has complex causes, is prone to recurrence even after treatment, and is difficult to cure completely. Because its clinical appearance and location vary, medication varies from person to person, and different types of eczema require different treatments.

[0003] Currently, there are many medications available for treating eczema, but different medications have different effects. Moreover, the prescriptions given by different traditional Chinese medicine experts are completely different. For patients with acute or subacute eczema, some patients take Jinchan Zhiyang Capsules orally, but the effectiveness rate is relatively poor. Some patients use Western medicine treatment, which may be effective quickly, but Western medicine treatment has many side effects and is prone to recurrence.

[0004] The information disclosed in this background section is intended only to enhance the understanding of the overall background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art known to those skilled in the art. Summary of the Invention

[0005] The purpose of this invention is to provide a Zhuang medicine formula called Shidu Xiaotang for treating eczema. This formula is effective, reliable, and has few side effects in treating acute and subacute eczema.

[0006] Another object of the present invention is to provide a method for preparing the Zhuang medicine Shidu Xiaotang for treating eczema.

[0007] To achieve the above objectives, the present invention provides a Zhuang medicine formula for treating eczema called Shidu Xiaotang, which is mainly composed of a first composition and a second composition. The raw materials of the first composition include: Smilax glabra, Polygonum aviculare, Abrus precatorius, Scutellaria baicalensis, Atractylodes macrocephala, and Saposhnikovia divaricata. The raw materials of the second composition include: Dictamnus dasycarpus, Lonicera japonica, Lithospermum erythrorhizon, Prunus mume, Stellaria dichotoma, Schisandra chinensis, Ficus hirta, Portulaca oleracea, Glycyrrhiza uralensis, and Astragalus membranaceus.

[0008] Preferably, in the above technical solution, the Zhuang medicine Shidu Xiaotang for treating eczema, by weight, comprises the following raw materials in the first composition: 20-40 parts of Smilax glabra, 6-15 parts of Polygonum aviculare, 20-40 parts of Abrus precatorius, 6-15 parts of Trichosanthes kirilowii, 6-15 parts of Atractylodes macrocephala, and 6-15 parts of Saposhnikovia divaricata.

[0009] Preferably, in the above technical solution, the Zhuang medicine Shidu Xiaotang for treating eczema, by weight, comprises: 30 parts of Smilax glabra, 10 parts of Polygonum aviculare, 10 parts of Abrus precatorius, 10 parts of Trichosanthes kirilowii, 10 parts of Atractylodes macrocephala, and 10 parts of Saposhnikovia divaricata.

[0010] Preferably, in the above technical solution, the Zhuang medicine Shidu Xiaotang for treating eczema, by weight, comprises the following raw materials in the second composition: 15-30 parts of Dictamnus dasycarpus root bark, 10-20 parts of Lonicera japonica vine, 5-15 parts of Lithospermum erythrorhizon root, 15-30 parts of Prunus mume fruit, 5-15 parts of Stellaria dichotoma root, 5-15 parts of Schisandra chinensis fruit, 15-30 parts of Ficus hirta fruit, 5-15 parts of Portulaca oleracea fruit, 4-8 parts of Glycyrrhiza uralensis root, 20-30 parts of Astragalus membranaceus root, and 10-20 parts of Artemisia capillaris fruit.

[0011] Preferably, in the above technical solution, the Zhuang medicine Shidu Xiaotang for treating eczema, by weight, comprises the following raw materials in the second composition: 20 parts of Dictamnus dasycarpus root bark, 15 parts of Lonicera japonica vine, 10 parts of Lithospermum erythrorhizon root, 20 parts of Prunus mume, 10 parts of Stellaria dichotoma root, 10 parts of Schisandra chinensis fruit, 20 parts of Ficus hirta fruit, 10 parts of Portulaca oleracea fruit, 6 parts of Glycyrrhiza uralensis root, 25 parts of Astragalus membranaceus root, and 15 parts of Artemisia capillaris fruit.

[0012] This application also provides a method for preparing the Zhuang medicine Shidu Xiaotang for treating eczema, comprising the following steps:

[0013] (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately.

[0014] (2) Weigh the raw materials of the second composition according to the weight proportions, and rinse and dry the following ingredients separately: Dictamnus dasycarpus root bark, Lonicera japonica vine, Lithospermum erythrorhizon root, Prunus mume, Stellaria dichotoma root, Schisandra chinensis fruit, Ficus hirta fruit, Portulaca oleracea root, Glycyrrhiza uralensis root, Astragalus membranaceus root, and Artemisia capillaris root; and set aside.

[0015] (3) Add 3-5 times the amount of water to the first and second compositions, simmer over low heat to concentrate and then package.

[0016] Preferably, in the above technical solution, each bag contains 200ml to 300ml.

[0017] The drug raw materials used in this invention have the following drug mechanism:

[0018] Smilax glabra: Its properties are sweet, bland, and neutral; it enters the liver and stomach meridians; its functions are to detoxify, eliminate dampness, and promote joint mobility; it is mainly used to treat limb contractures and muscle and bone pain caused by syphilis and mercury poisoning; damp-heat urinary tract infections, leukorrhea, carbuncles, scrofula, and scabies.

[0019] Poria cocos: Taste and nature: sour, slightly cold; Meridian tropism: lung and bladder; Functions: clearing heat and detoxifying, promoting diuresis and reducing swelling, relieving cough; Indications: sore throat, cough due to lung heat, whooping cough in children, edema with scanty urine, diarrhea due to damp heat, eczema, boils, snake and insect bites.

[0020] Chicken bone grass, tastes sweet and slightly bitter, cool in nature, enters the liver and stomach meridians, functions to promote diuresis and relieve jaundice, clear heat and detoxify, soothe the liver and relieve pain, mainly treats damp-heat jaundice, discomfort in the hypochondrium, abdominal distension and pain, and mastitis.

[0021] Three-forked bitter herb, taste: bitter, cold; function: clearing heat and detoxifying, dispelling wind and dampness; main indications: sore throat, rheumatic bone pain, malaria, jaundice, eczema, dermatitis, traumatic injuries, and insect and snake bites.

[0022] Atractylodes macrocephala, bitter and sweet in taste, warm in nature, and enters the spleen and stomach meridians, generally has the effects of tonifying qi and strengthening the spleen, drying dampness and promoting diuresis, and stopping sweating. Clinically, it is mainly used to treat spleen qi deficiency, spleen deficiency stagnation, spleen deficiency with fluid retention, phlegm retention, excessive sweating due to weak skin surface, and threatened abortion. Atractylodes macrocephala contains nutrients such as atractylodes alcohol, dehydrated atractylodes lactone, palmitic acid, fructose, inulin, resin, and vitamin A, and has the effects of tonifying qi and strengthening the spleen, and enhancing the body.

[0023] Saposhnikovia divaricata, its flavor is pungent and sweet, and its nature is slightly warm; it enters the bladder, spleen, and liver meridians; it is mainly used for external pathogenic factors, rashes and itching, rheumatic pain, tetanus, and spleen deficiency with dampness.

[0024] Dictamnus dasycarpus root bark, taste: bitter, cold; meridians: spleen, stomach, bladder; functions: damp-heat sores and toxic sores, weeping sores, eczema, urticaria, scabies, and rheumatic arthralgia.

[0025] Honeysuckle vine, its properties are sweet and cold; its functions are clearing heat, detoxifying, and unblocking the meridians; it is mainly used to treat febrile diseases, dysentery caused by heat toxins, infectious hepatitis, carbuncles and boils, and muscle and bone pain.

[0026] Purple gromwell root is sweet, salty, and cold in nature. It cools the blood, invigorates blood circulation, detoxifies, and promotes rash eruption. It is mainly used to treat blood heat and toxicity, purplish-black rashes, incomplete measles eruption, eczema, sores, and burns.

[0027] Ume plum, in terms of taste, is sour and astringent, and neutral in nature; it enters the liver, spleen, lung, and large intestine meridians; its functions include astringing the lungs, astringing the intestines, promoting the production of body fluids, and expelling roundworms; it is mainly used for chronic cough due to lung deficiency, chronic diarrhea and dysentery, thirst due to deficiency heat, and vomiting and abdominal pain due to roundworm infestation.

[0028] Yin Chai Hu (Radix Stellariae), in terms of its properties and channels, is sweet and bitter, and cool in nature. Its functions and indications include clearing deficiency heat and eliminating infantile malnutrition fever. It is used for fever due to yin deficiency, steaming bone fever, and infantile malnutrition fever.

[0029] Schisandra chinensis has a sour and sweet taste and a warm nature. It enters the lung, heart, and kidney meridians. Its functions include astringing and consolidating, replenishing qi and promoting body fluids, tonifying the kidneys and calming the mind. It is used for chronic cough and wheezing, nocturnal emission and spermatorrhea, enuresis and frequent urination, chronic diarrhea, spontaneous sweating and night sweats, thirst due to fluid depletion, internal heat and thirst, palpitations and insomnia.

[0030] Five-finger peach, its taste is sweet and its nature is neutral; it enters the spleen, lung and liver meridians; its functions are to strengthen the spleen and lungs, promote qi circulation and eliminate dampness, relax muscles and tendons; it is mainly used to treat spleen deficiency edema, poor appetite and weakness, pulmonary tuberculosis cough, night sweats, leukorrhea, postpartum agalactia, rheumatic pain, edema, ascites due to cirrhosis, hepatitis, and traumatic injuries.

[0031] Purslane, in terms of taste and nature, is sour and cold; it enters the liver and large intestine meridians; its functions are to clear heat and detoxify, cool the blood and stop bleeding, and stop dysentery; it is used to treat dysentery caused by heat toxins, carbuncles and boils, eczema, erysipelas, snake and insect bites, hematochezia, hemorrhoidal bleeding, and metrorrhagia.

[0032] Licorice root, in terms of taste, is sweet and neutral; it enters the heart, lung, spleen, and stomach meridians; its functions include tonifying the spleen and replenishing qi, clearing heat and detoxifying, resolving phlegm and relieving cough, relieving spasms and pain, and harmonizing other herbs; it is mainly used for spleen and stomach weakness, fatigue, palpitations and shortness of breath, cough with excessive phlegm, abdominal and limb spasms and pain, carbuncles and boils, and to alleviate the toxicity and harshness of other drugs.

[0033] Astragalus membranaceus, in terms of its properties and channels, is sweet and slightly warm in nature; it enters the spleen and lung channels; its functions include strengthening the spleen and replenishing the middle jiao, raising yang and lifting prolapse, benefiting wei qi and consolidating the exterior, promoting diuresis, and promoting tissue regeneration and detoxification.

[0034] Artemisia capillaris has a bitter and pungent taste, and is slightly cold in nature. It enters the spleen, stomach, liver, and gallbladder meridians. Its functions include clearing damp-heat, promoting bile secretion, and relieving jaundice. It is mainly used for jaundice with scanty urine, damp-heat syndrome, and itchy sores.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] (1) The Zhuang medicine Shidu Xiaotang for treating eczema of the present invention is based on the first composition and supplemented by the second composition. Specifically, the first composition is based on Smilax glabra, Scutellaria baicalensis, Abrus precatorius, and Polygonum aviculare as the principal herbs for clearing heat, detoxifying, dispelling wind and dampness. It is combined with Lonicera japonica, Dictamnus dasycarpus, Glycyrrhiza uralensis, Portulaca oleracea, Ficus hirta, Bupleurum chinense, Schisandra chinensis, Lithospermum erythrorhizon, Prunus mume, Astragalus membranaceus, and Artemisia capillaris to clear heat, detoxify, dispel wind and dampness, clear heat, detoxify, and promote diuresis, and harmonize the herbs. Furthermore, the second composition improves the effect of the first composition on the changes of damp-heat syndrome. Starting from clearing heat, promoting diuresis and detoxifying, it improves the state of damp-heat accumulation in the skin and the skin lesions of clinical patients, so that patients can better accept and effectively absorb it, thereby preventing the recurrence of eczema.

[0037] (2) The Zhuang medicine Shidu Xiaotang used in this invention to treat eczema can effectively improve the TCM syndrome score, EASI score, pruritus score, and Dermatology Quality of Life Index (DLQI) score of eczema patients, thus effectively improving the clinical problems of eczema patients and improving their quality of life.

[0038] (3) The present invention can effectively inhibit acute eczema and subacute eczema. The preparation method is relatively simple and easy to produce on a large scale.

[0039] Instruction manual illustrations

[0040] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the structures shown in these drawings without creative effort.

[0041] Figure 1 This is a comparison of body weight of mice in the blank group, model group, and disease-symptom combination group treated for 14 days in the basic research section of this application.

[0042] Figure 2 The changes in mouse skin lesions were shown in the skin lesion inflammation scores of the blank group, model group, positive control group, and Zhuang medicine group in the basic research section of this application on days 7, 14, and 21.

[0043] Figures 3-5 The results of skin lesion inflammation scores on days 7, 14, and 21 for the blank group, model group, positive control group, and Zhuang medicine group in this application;

[0044] Figures 6-8 The scores of damp-heat syndrome in traditional Chinese medicine for the blank group, model group, positive control group and Zhuang medicine group in this application on days 7, 14 and 21;

[0045] Figure 9 The serum IL-4 levels of mice in each group in this application;

[0046] Figure 10 Serum IgE levels in mice from each group in this application;

[0047] Figure 11 These are pathological images of skin lesions in mice from each group in this application. Detailed Implementation

[0048] The specific embodiments of the present invention will be described in detail below with reference to specific examples, but it should be understood that the scope of protection of the present invention is not limited to the specific embodiments.

[0049] Example 1

[0050] A traditional Chinese medicine for treating eczema, Shidu Xiaotang, is mainly composed of a first composition and a second composition.

[0051] By weight, the raw materials of the first composition include: 20 parts of Smilax glabra, 6 parts of Polygonum aviculare, 6 parts of Abrus precatorius, 6 parts of Scutellaria baicalensis, 6 parts of Atractylodes macrocephala, and 6 parts of Saposhnikovia divaricata.

[0052] The raw materials of the second composition, by weight, include: 15 parts of Dictamnus dasycarpus root bark, 10 parts of Lonicera japonica vine, 5 parts of Lithospermum erythrorhizon root, 15 parts of Prunus mume, 5 parts of Stellaria dichotoma root, 5 parts of Schisandra chinensis fruit, 15 parts of Ficus hirta fruit, 5 parts of Portulaca oleracea fruit, 4g of Glycyrrhiza uralensis root, 20 parts of Astragalus membranaceus root, and 10 parts of Artemisia capillaris fruit.

[0053] The preparation method of the above-mentioned Zhuang medicine formula for damp-heat toxicity includes the following steps:

[0054] (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately.

[0055] (2) Weigh the raw materials of the second composition according to the weight parts, and rinse and dry the white peony bark, honeysuckle vine, purple gromwell root, dried plum, silver bupleurum root, schisandra fruit, five-finger peach, purslane, licorice, astragalus root, and artemisia capillaris separately for later use.

[0056] (3) Add water equal to three times the volume of the first and second compositions, simmer over low heat to concentrate, and then package into bags of 300ml each.

[0057] The present invention relates to a Zhuang medicine formula called Shidu Xiaotang for treating eczema. The method of use is to take 300ml three times a day for 14 days as one course of treatment.

[0058] Example 2

[0059] A traditional Chinese medicine for treating eczema, Shidu Xiaotang, is mainly composed of a first composition and a second composition.

[0060] The raw materials of the first composition, by weight, include: 30 parts of Smilax glabra, 10 parts of Polygonum aviculare, 10 parts of Abrus precatorius, 10 parts of Trichosanthes kirilowii, 10 parts of Atractylodes macrocephala, and 10 parts of Saposhnikovia divaricata.

[0061] The raw materials of the second composition, by weight, include: 20 parts of Dictamnus dasycarpus root bark, 15 parts of Lonicera japonica vine, 10 parts of Lithospermum erythrorhizon root, 20 parts of Prunus mume, 10 parts of Stellaria dichotoma root, 10 parts of Schisandra chinensis fruit, 20 parts of Ficus hirta fruit, 10 parts of Portulaca oleracea fruit, 6g of Glycyrrhiza uralensis root, 25 parts of Astragalus membranaceus root, and 15 parts of Artemisia capillaris fruit.

[0062] The preparation method of the above-mentioned Zhuang medicine formula for damp-heat toxicity includes the following steps:

[0063] (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately.

[0064] (2) Weigh the raw materials of the second composition according to the weight parts, and rinse and dry the white peony bark, honeysuckle vine, purple gromwell root, dried plum, silver bupleurum root, schisandra fruit, five-finger peach, purslane, licorice, astragalus root, and artemisia capillaris separately for later use.

[0065] (3) Add water equal to 4 times the volume of the first and second compositions, simmer over low heat to concentrate, and then package into bags of 250ml each.

[0066] The present invention relates to a Zhuang medicine formula called Shidu Xiaotang for treating eczema. The method of use is to take 250ml three times a day for 14 days as one course of treatment.

[0067] Example 3

[0068] A traditional Chinese medicine called Shidu Xiaotang for treating eczema is mainly composed of a first composition and a second composition.

[0069] The raw materials of the first composition, by weight, include: 40 parts of Smilax glabra, 15 parts of Polygonum aviculare, 15 parts of Abrus precatorius, 15 parts of Scutellaria baicalensis, 15 parts of Atractylodes macrocephala, and 15 parts of Saposhnikovia divaricata.

[0070] The raw materials of the second composition, by weight, include: 30 parts of Dictamnus dasycarpus root bark, 20 parts of Lonicera japonica vine, 15 parts of Lithospermum erythrorhizon root, 30 parts of Prunus mume, 15 parts of Stellaria dichotoma root, 15 parts of Schisandra chinensis fruit, 30 parts of Ficus hirta fruit, 15 parts of Portulaca oleracea fruit, 8 parts of Glycyrrhiza uralensis root, 30 parts of Astragalus membranaceus root, and 20 parts of Artemisia capillaris fruit.

[0071] The preparation method of the above-mentioned Zhuang medicine formula for damp-heat toxicity includes the following steps:

[0072] (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately.

[0073] (2) Weigh the raw materials of the second composition according to the weight parts, and rinse and dry the white peony bark, honeysuckle vine, purple gromwell root, dried plum, silver bupleurum root, schisandra fruit, five-finger peach, purslane, licorice, astragalus root, and artemisia capillaris separately for later use.

[0074] (3) Add water equal to 5 times that of the first and second compositions, simmer over low heat to concentrate, and then package into bags of 200ml each.

[0075] The present invention relates to a Zhuang medicine formula called Shidu Xiaotang for treating eczema. The method of use is to take 200ml three times a day for 14 days as one course of treatment.

[0076] Example 4

[0077] A traditional Chinese medicine called Shidu Xiaotang for treating eczema is mainly composed of a first composition and a second composition.

[0078] The raw materials of the first composition, by weight, include: 25 parts of Smilax glabra, 8 parts of Polygonum aviculare, 8 parts of Abrus precatorius, 8 parts of Scutellaria baicalensis, 8 parts of Atractylodes macrocephala, and 8 parts of Saposhnikovia divaricata.

[0079] The raw materials of the second composition, by weight, include: 18 parts of Dictamnus dasycarpus root bark, 12 parts of Lonicera japonica vine, 8 parts of Lithospermum erythrorhizon root, 18 parts of Prunus mume, 8 parts of Stellaria dichotoma root, 8 parts of Schisandra chinensis fruit, 18 parts of Ficus hirta fruit, 8 parts of Portulaca oleracea fruit, 5 parts of Glycyrrhiza uralensis root, 22 parts of Astragalus membranaceus root, and 12 parts of Artemisia capillaris fruit.

[0080] The preparation method of the above-mentioned Zhuang medicine formula for damp-heat toxicity includes the following steps:

[0081] (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately.

[0082] (2) Weigh the raw materials of the second composition according to the weight parts, and rinse and dry the white peony bark, honeysuckle vine, purple gromwell root, dried plum, silver bupleurum root, schisandra fruit, five-finger peach, purslane, licorice, astragalus root, and artemisia capillaris separately for later use.

[0083] (3) Add water equal to 5 times that of the first and second compositions, simmer over low heat to concentrate, and then package into bags of 200ml each.

[0084] The present invention relates to a Zhuang medicine formula called Shidu Xiaotang for treating eczema. The method of use is to take 200ml three times a day for 14 days as one course of treatment.

[0085] Example 5

[0086] A traditional Chinese medicine called Shidu Xiaotang for treating eczema is mainly composed of a first composition and a second composition.

[0087] The raw materials of the first composition, by weight, include: 35 parts of Smilax glabra, 12 parts of Polygonum aviculare, 12 parts of Abrus precatorius, 12 parts of Trichosanthes kirilowii, 12 parts of Atractylodes macrocephala, and 12 parts of Saposhnikovia divaricata.

[0088] The raw materials of the second composition, by weight, include: 25 parts of Dictamnus dasycarpus root bark, 17 parts of Lonicera japonica vine, 12 parts of Lithospermum erythrorhizon root, 25 parts of Prunus mume, 12 parts of Stellaria dichotoma root, 12 parts of Schisandra chinensis fruit, 25 parts of Ficus hirta fruit, 8 parts of Portulaca oleracea fruit, 5 parts of Glycyrrhiza uralensis root, 28 parts of Astragalus membranaceus root, and 18 parts of Artemisia capillaris fruit.

[0089] The preparation method of the above-mentioned Zhuang medicine formula for damp-heat toxicity includes the following steps:

[0090] (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately.

[0091] (2) Weigh the raw materials of the second composition according to the weight parts, and rinse and dry the white peony bark, honeysuckle vine, purple gromwell root, dried plum, silver bupleurum root, schisandra fruit, five-finger peach, purslane, licorice, astragalus root, and artemisia capillaris separately for later use.

[0092] (3) Add water equal to 4 times the volume of the first and second compositions, simmer over low heat to concentrate, and then package into bags of 200ml each.

[0093] The present invention relates to a Zhuang medicine formula called Shidu Xiaotang for treating eczema. The method of use is to take 200ml three times a day for 14 days as one course of treatment.

[0094] First, clinical research

[0095] 1. Clinical Data

[0096] 1.1 Observation Object

[0097] Eighty patients with eczema (damp-heat accumulation in the skin) who visited the Department of Dermatology and Venereology at the Affiliated Ruikang Hospital of Guangxi University of Chinese Medicine between June 2021 and June 2022 were selected. They were randomly divided into a treatment group and a control group (n=40 each) according to their order of visit using a random number table. This study was approved by the Ethics Committee of the Affiliated Ruikang Hospital of Guangxi University of Chinese Medicine (No.: KY2021-108). Patients were informed of the study protocol and purpose, and all patients voluntarily participated, signing informed consent forms, which were recorded and archived.

[0098] 1.2 Diagnostic criteria

[0099] (1) Western medicine diagnostic criteria: Refer to the diagnostic criteria for acute eczema in "Chinese Clinical Dermatology": the skin lesions are polymorphic, and erythema, edema, papules, vesicles or vesicles may appear at the same time, with varying degrees of erosion and exudation, accompanied by persistent itching.

[0100] (2) Traditional Chinese Medicine Diagnostic Criteria: Referring to the "Expert Consensus on the Diagnosis and Treatment of Eczema (Wet Sores) in Traditional Chinese Medicine (2021)" and the "Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs", the main symptoms are: red skin lesions, papules, vesicles, and blisters may appear simultaneously, with erosion and exudation, burning sensation to the touch, and itching; secondary symptoms include: irritability, fever, dry mouth, yellow urine, and constipation; tongue and pulse: red tongue with yellow and greasy or thin yellow coating, and slippery or rapid pulse. Patients with two or more of the main and secondary symptoms can be diagnosed with damp-heat accumulation in the skin.

[0101] 1.3 Inclusion criteria: (1) Meets the Western medicine diagnostic criteria for acute eczema and the traditional Chinese medicine diagnostic criteria for damp-heat syndrome. (2) Age 18–60 years. (3) Signed informed consent form and voluntarily joined this study.

[0102] 1.4 Exclusion criteria: (1) Allergy to the test drug or its components; (2) Use of steroid drugs within the past two weeks and / or use of antihistamines or topical steroids within the past week; (3) Exclusion criteria for patients with serious primary diseases; (4) Patients with obvious erosion, ulceration and exudation at the skin lesion site and bacterial infection or positive fungal microscopy; (5) Patients who are unable to cooperate with the test independently; (6) Patients who refuse to participate in this clinical study.

[0103] 1.5 Exclusion criteria: (1) Patients found to have serious primary diseases after enrollment; (2) Patients who took other drugs that affected the efficacy evaluation of this clinical study after enrollment; (3) Patients with poor compliance during the trial, who did not follow the doctor's orders for treatment, and whose efficacy could not be judged.

[0104] 1.6 Dropout criteria: (1) Patients who withdraw midway or voluntarily withdraw their informed consent due to non-therapeutic factors.

[0105] 2. Test methods

[0106] 2.1 Treatment methods:

[0107] (1) The treatment group used Zhuang medicine Shidu Xiaotang orally, which was prepared by the drug research and development base of the Affiliated Ruikang Hospital of Guangxi University of Traditional Chinese Medicine, concentrated and packaged in bags of 200 mL each. The prescription composition is as described in Example 2.

[0108] (2) The control group took Jinchan Zhiyang Capsules (Chongqing Xieran Pharmaceutical Co., Ltd., National Drug Approval Number) orally, 6 capsules / time, 3 times / day.

[0109] 2.2 Observation indicators: The TCM syndrome score, EASI score, pruritus score, DLQI score, serum immune indicators and inflammatory factor levels of patients in each group before and after treatment were observed.

[0110] (1) Traditional Chinese Medicine Syndrome Scoring Standard: The main symptoms include red skin lesions, papules, vesicles, blisters, erosion, exudation, and itching. The scores are 0, 2, 4, and 6 for none, mild, moderate, and severe. The secondary symptoms include irritability, fever, dry mouth, yellow urine, and constipation. The scores are 0, 1, 2, and 3 for none, mild, moderate, and severe.

[0111] (2) Eczema area and severity index (EASI) and pruritus score[6];

[0112] (3) Dermatology Life Quality Index (DLQI) score [7], see Table 3. The content includes physical symptoms, psychological status, social function, treatment and nursing care, etc., a total of 10 questions, which are divided into no impact: 0 points; mild: 1 point; severe: 2 points; very severe: 3 points. A total score of 0-1 points indicates no impact, 2-5 points indicates mild impact, 6-20 points indicates moderate impact, and 21-30 points indicates extremely severe impact. The DLQI scores of the two groups of patients were recorded before and after treatment, and each score was negatively correlated with their quality of life.

[0113] (4) Serum inflammatory factor levels: Fasting antecubital venous blood samples were collected from both groups of patients, with a collection volume of 4.0 ml. After centrifugation, the supernatant was collected, and the serum IgE, IL-4, and IL-6 were detected. The above indicators were all detected using an enzyme-linked immunosorbent assay (ELISA) kit, and two laboratory personnel performed quantitative detection and statistical analysis according to the kit instructions.

[0114] 2.3 Criteria for Efficacy Judgment (1) Clinically Cured: All skin lesions have disappeared, and the skin has completely returned to normal or only pigmentation remains. The patient feels no itching at all, and the TCM syndrome score is ≥95%; (2) Significantly Effective: Most of the rash has disappeared, 100% > the rash area has shrunk by ≥70%, the itching is mild, the patient scratches occasionally, and it does not affect sleep, 95% > the TCM syndrome score has decreased by ≥70%; (3) Effective: Partially disappearing skin lesions, 70% > the rash area has shrunk by ≥50%, the itching is obvious, the patient scratches frequently, and it affects sleep, 75% > the TCM syndrome score has decreased by ≥50%; (4) Ineffective: Skin lesions have not disappeared significantly, the rash area has shrunk by <50%, or has even enlarged, the itching is severe, the patient scratches constantly, and it seriously affects sleep, and the TCM syndrome score has decreased by <50%. If any criterion is not met, the standard will be lowered by one. Total effective rate = [(number of cured cases + number of significantly effective cases + number of effective cases) / total number of cases] × 100%.

[0115] 2.4 Statistical Analysis SPSS 27.0 statistical software was used for statistical analysis. Quantitative data were expressed as mean ± standard deviation (±S) and analyzed using t-tests. Count data were expressed as number of cases and percentages (%) and analyzed using chi-square tests. A p-value < 0.05 was considered statistically significant.

[0116] 3 Results

[0117] 3.1 Comparison of Completion Status and General Information between the Two Groups: In the treatment group, 3 patients requested to discontinue treatment due to work reasons; in the control group, 2 patients were lost to follow-up, and 2 patients discontinued treatment due to poor compliance. Ultimately, 37 patients completed the observation in the treatment group and 36 patients completed it in the control group. There were no statistically significant differences in age, gender, and disease duration between the two groups (P>0.05), making them comparable. Please refer to Table 1 for details.

[0118] Table 1 Comparison of general characteristics between the two groups of patients (n, ±S)

[0119]

[0120] 3.2 Comparison of clinical efficacy between the two groups: The total effective rates of the treatment group and the control group were 83.78% and 52.78%, respectively. The treatment group was superior to the control group (P<0.05). Please refer to Table 2 for details.

[0121] Table 2 Comparison of clinical efficacy between the two groups of patients [n(%)]

[0122]

[0123] Note: Compared with the control group, ① P<0.05

[0124] 3.3 Comparison of TCM syndrome scores before and after treatment in the two groups: Before treatment, there was no significant difference in TCM syndrome scores between the two groups (P>0.05); after treatment, the TCM syndrome scores of both groups were significantly improved compared with those before treatment, and the difference was statistically significant (P<0.05). The TCM syndrome score of the treatment group was better than that of the control group (P<0.05), please refer to Table 3.

[0125] Table 3 Comparison of TCM syndrome scores before and after treatment in the two groups of patients (±S, points)

[0126]

[0127]

[0128] Note: There was no statistically significant difference in TCM syndrome scores between the two groups before treatment (P>0.05); compared with the same group before treatment, ①P<0.01; compared with the control group after treatment, ②P<0.05.

[0129] 3.4 Comparison of EASI scores, pruritus scores, and DLQI scores before and after treatment in the two groups Before treatment, there were no significant differences in EASI scores, pruritus scores, and DLQI scores between the two groups (P>0.05). After treatment, EASI scores, pruritus scores, and DLQI scores in both groups were significantly improved compared with those before treatment, and the differences were statistically significant (P<0.01). Moreover, the degree of reduction in EASI scores, pruritus scores, and DLQI scores in the treatment group was better than that in the control group (P<0.05). Please refer to Table 4.

[0130] Table 4 Comparison of EASI, DLQI, and pruritus scores before and after treatment in the two groups (±S, points)

[0131]

[0132] Note: There were no statistically significant differences in any of the scoring scales between the two groups before treatment (P > 0.05); compared with the same group before treatment, ① P < 0.01; compared with the control group after treatment, ② P < 0.05.

[0133] 3.5 Comparison of serum IgE, IL-4, and IL-6 levels before and after treatment in both groups. Before treatment, there were no statistically significant differences in serum IgE, IL-4, and IL-6 levels between the two groups (P > 0.05). After treatment, serum IgE, IL-4, and IL-6 levels in both groups decreased compared to before treatment (P < 0.05), and the treatment group showed better results than the control group (P < 0.05). Please refer to Table 5 for details.

[0134] Table 5 Comparison of serum IgE, TNF-α, IL-4 and IL-6 levels before and after treatment in the two groups of patients (±S)

[0135]

[0136] Note: Before treatment, there were no statistically significant differences in serum IgE, IL-4, and IL-6 levels between the two groups (P > 0.05); compared with pre-treatment levels in the same group, ① P < 0.05; compared with the control group after treatment, ② P < 0.05.

[0137] 3.6 Comparison of adverse reactions among the groups During the treatment, no adverse reactions such as skin irritation or somatic symptoms occurred in either group.

[0138] II. Animal Experiments

[0139] Objective: To explore the method of inducing AD with exogenous substances through transdermal induction combined with TCM damp-heat syndrome to create a mouse model of AD with damp-heat syndrome, and to use Zhuang medicine Shidu Xiaotang for intervention, so as to provide experimental reference for the study of AD damp-heat syndrome model and the intervention of Zhuang medicine Shidu Xiaotang in AD.

[0140] Experiment 1: Thirty 6-week-old KM mice (15 males and 15 females) were randomly divided into three groups (n=10 each): a control group, a model group, and a disease-symptom combination group. An Alzheimer's disease (AD) damp-heat syndrome mouse model was established using a combination of exogenous substances inducing percutaneous induction and TCM damp-heat syndrome modeling. The control group and model group served as control references. Animal morphology was observed to assess the general condition of the mice, the degree of skin inflammation, and TCM damp-heat syndrome signs. Serum IgE and IL-4 expression were detected by ELISA. Pathological changes in the skin lesions were observed and analyzed.

[0141] Experiment 2: Forty 6-week-old KM mice (20 males and 20 females) were randomly divided into four groups (n=10 each): a blank control group, a model group, a positive control group, and a Zhuang medicine group. The model group, positive control group, and Zhuang medicine group were induced using a combination of exogenous substances through percutaneous induction and traditional Chinese medicine (TCM) damp-heat syndrome modeling. On day 15, the positive control group was administered prednisolone acetate tablets by gavage, the Zhuang medicine group was administered Zhuang medicine Shidu Xiaotang by gavage, and the blank control group and model group were administered an equal volume of physiological saline by gavage, once daily for 7 consecutive days. The general condition of the mice, the degree of skin inflammation, and the manifestations of TCM damp-heat syndrome were observed morphologically. Serum IgE and IL-4 expression were detected by ELISA, and pathological changes in the skin lesions were observed and analyzed.

[0142] Results: Experiment 1: Mice in the combined syndrome and disease group exhibited lethargy and reduced activity, with increased body weight and size compared to the initial modeling stage. The skin at the modeling site on the back of both the model and combined syndrome groups corresponded to the clinical manifestations of atopic dermatitis (AD). The combined syndrome group showed more severe inflammation, with a significantly higher inflammation score. The combined syndrome group exhibited dull fur, yellow urine, loose feces, and a strong odor; the damp-heat syndrome score gradually increased with the duration of the experiment. Serum IgE and IL-4 levels in the combined syndrome group were significantly higher than in the model and control groups. Both the model and combined syndrome groups showed epidermal thickening, hyperkeratosis, acanthosis, and widespread infiltration of inflammatory cells such as neutrophils and lymphocytes, consistent with the histopathological changes of atopic dermatitis lesions. These pathological changes were more pronounced in the combined syndrome group than in the model group.

[0143] Experiment 2: On day 21, mice in the model group and positive control group showed lethargy and reduced activity. Compared to day 14, their body weight increased, their abdomens became rounder, and they appeared slightly obese. Mice in the Zhuang medicine group showed relatively good activity levels, increased body weight, and a more symmetrical physique. The inflammation of skin lesions in the hairless areas on the backs of mice in both the positive control and Zhuang medicine groups improved. The inflammation scores of skin lesions in the positive control and Zhuang medicine groups were lower than those in the model group; the inflammation score in the Zhuang medicine group was lower than that in the positive control group. The symptoms of damp-heat syndrome in both the model and positive control groups worsened, with increased damp-heat syndrome scores. Compared to the model group, there was no statistically significant difference in damp-heat syndrome scores in the positive control group, while the damp-heat syndrome score in the Zhuang medicine group was lower. After intervention, serum IgE and IL-4 levels in mice in both the positive control and Zhuang medicine groups significantly decreased. Histopathological findings in the skin lesions of mice in the Zhuang medicine and positive control groups showed mild hyperkeratosis, reduced epidermal thickness and acanthosis, and less inflammatory cell infiltration compared to the model group. Compared with the Zhuang medicine group, the positive control group still had a small amount of inflammatory cell infiltration and a thicker epidermis.

[0144] Conclusion: The modeling method combining exogenous substance transdermal induction with TCM damp-heat syndrome factor modeling can establish an animal model that conforms to the characteristics of AD damp-heat syndrome. Zhuang medicine Shidu Xiaotang can downregulate serum IgE and IL-4 levels in AD damp-heat syndrome mice, reduce the degree of skin inflammation, improve skin tissue structure, and alleviate damp-heat symptoms in mice.

[0145] 1. General situation

[0146] On day 14 of the experiment, mice in the blank group and the model group were in good spirits, active normally, and had shiny fur. Compared with the early stage of modeling, the mice had increased body weight and size. Mice in the disease-symptom combination group were lethargic and less active. Compared with the early stage of modeling, their body weight and size had increased.

[0147] On day 14 of the experiment, compared with the control group and the model group, the body weight of mice in the combined disease and syndrome group increased significantly (P<0.05). Please refer to Table 6 and... Figure 1 The results suggest that the combined effects of a high-fat, high-sugar diet and a hot, humid environment on the body weight of the mice in the disease-symptom combination group had a certain impact.

[0148] Table 6. Body weight changes of mice in each group at 0, 7, and 14 days (±s, n=10)

[0149]

[0150] Note: Compared with the control group: *P<0.05; Compared with the model group: #P<0.05;

[0151] 2. Skin lesion inflammation score

[0152] On day 5 after applying calcipotriol, mice in both the model group and the combined disease and symptom group exhibited rough, thickened skin on their backs, along with erythema and a few scratch marks, and scratching behavior. As the modeling process progressed, the skin damage worsened, with more pronounced erythema and scratch marks in the affected areas, along with fine scales and rice-grain-sized papules, and frequent scratching. On day 14, the skin on the backs of both the model group and the combined disease and symptom group was rough, thickened, and dry, with increased scratch marks, erythema, petechiae, scales, and epidermal shedding. Hair growth was slow, sparse, and dull, and scratching behavior became increasingly frequent. The skin at the modeling site was consistent with the clinical manifestations of Alzheimer's disease (AD). The erythema and scaling in the combined disease and symptom group were more severe than in the model group. In contrast, the hairless area on the back of the control group showed no significant change compared to before modeling, and the hair grew back and became shiny.

[0153] On day 7, compared with the control group, the skin lesion inflammation scores of both the model group and the combined disease-symptom group were significantly increased (P<0.01); compared with the model group, there was no significant difference in skin lesion inflammation scores in the combined disease-symptom group (P>0.05). On day 14, compared with the control group, the skin lesion inflammation scores of both the model group and the combined disease-symptom group were significantly increased (P<0.01); compared with the model group, the skin lesion inflammation score of the combined disease-symptom group was significantly increased (P<0.01). Please refer to [link to relevant documentation] for details. Figures 2-5 and Table 7,

[0154] Table 7. Skin lesion inflammation scores of mice in each group on days 7, 14, and 21 (±s, n=10)

[0155]

[0156] Note: Compared with the control group: *P < 0.05, **P < 0.01, nxP > 0.05; Compared with the model group: #P < 0.05, ##P

[0157] <0.01; nsP>0.05;

[0158] 3. Traditional Chinese Medicine Damp-Heat Syndrome Score

[0159] On day 14 of the experiment, mice in the blank group showed good mental activity, good fur color, and increased body weight and morphology compared to the early stage of modeling; mice in the model group, positive control group, and Zhuang medicine group showed moderate mental activity, increased body weight and morphology compared to the early stage of modeling, dull fur, yellow urine, and strong fecal odor.

[0160] On day 21 of the experiment, mice in the blank control group showed good mental activity, with a few mice showing decreased activity, and their body weight and morphology increased compared to day 14. Mice in the model group and positive control group showed significantly reduced activity, lethargy, increased body weight and morphology compared to day 14, dull fur, bright yellow urine, loose stools, and a strong odor. Mice in the Zhuang medicine group showed normal mental activity, increased body weight and morphology compared to day 14, yellow urine, and a few mice had a strong odor in their feces.

[0161] On day 14 of the experiment, compared with the blank group, the damp-heat syndrome scores of the model group, positive control group, and Zhuang medicine group gradually increased over time, with statistically significant differences (P<0.01); compared with the model group, there was no significant difference in damp-heat syndrome scores between the positive control group and the Zhuang medicine group (P>0.05). On day 21 of the experiment, compared with the model group, there was no statistically significant difference in damp-heat syndrome scores between the positive control group and the Zhuang medicine group (P>0.05), while the damp-heat syndrome scores of the Zhuang medicine group decreased, with a statistically significant difference (P<0.01). Figure 6-8 Table 8 shows that the Zhuang medicine Shidu Xiaotang can improve the symptoms of damp-heat syndrome in mice and reduce the damp-heat syndrome score, while prednisolone acetate tablets have no significant effect on the symptoms of damp-heat syndrome in mice.

[0162] Table 8. Damp-heat syndrome scores of mice in each group on days 7, 14, and 21 (±s, n=10)

[0163]

[0164] Note: Compared with the control group: *P<0.05, **P<0.01, nxP>0.05; Compared with the model group: #P<0.05, ##P<0.01; nsP>0.05

[0165] 4. Serum IgE and IL-4 levels

[0166] The results showed that, compared with the blank control group, the serum IgE level in the model group mice (112.61±43.15 ng / mL) was significantly higher than that in the blank control group (59.44±4.91 ng / mL), with a statistically significant difference (P<0.01). There was no significant difference in serum IgE level in the Zhuang medicine group mice (P>0.05). Compared with the model group, the serum IgE level in the positive control group (81.3±3.25 ng / mL) and the Zhuang medicine group mice was decreased (69.79±3.12 ng / mL), with statistically significant differences (P<0.01). Figure 9 Table 9.

[0167] Compared with the blank group (10.32±2.12 pg / mL), the serum IL-4 level in the model group mice (17.32±3.89 pg / mL) was significantly higher than that in the blank group, with a statistically significant difference (P<0.01). Compared with the serum IL-4 level in the model group, the levels in the positive control group (13.66±2.45 pg / mL) and the Zhuang medicine group (12.41±2.21 pg / mL) were decreased, with statistically significant differences (P<0.01). Figure 10 Table 9.

[0168] After intervention, the serum IgE and IL-4 levels of mice in the positive control group and the Zhuang medicine group were significantly improved, indicating that both prednisolone acetate tablets and Zhuang medicine Shidu Xiaotang can reduce the serum IgE and IL-4 levels in mice. There was no significant difference between the two regimens in downregulating the serum IgE and IL-4 levels in AD damp-heat syndrome mice.

[0169] Table 9. IgE and IL-4 levels in mice of each group (±s, n=10)

[0170]

[0171] Note: Compared with the control group: *P<0.05, **P<0.01; Compared with the model group: #P<0.05, ##P<0.01

[0172] 5. HE staining pathological histological observation

[0173] HE staining results showed that the epidermis and dermis of the skin tissue of mice in the blank group were relatively intact, with no obvious abnormalities, normal cell morphology, and no obvious infiltration of inflammatory cells such as lymphocytes and neutrophils. No obvious inflammatory reaction was observed in the superficial dermis, the skin appendages were neatly arranged, and there was no edema or necrosis in the tissue.

[0174] The model group showed hyperkeratosis, thickening of the epidermal spinous cell layer, thickening of the epidermal layer, and extensive infiltration of inflammatory cells such as neutrophils and lymphocytes in the superficial dermis, consistent with the pathological and histological changes of atopic dermatitis.

[0175] Compared with the model group, the pathological differences in the Zhuang medicine group and the positive control group mice were mild hyperkeratosis, reduced epidermal thickness and acanthosis, and reduced inflammatory cell infiltration.

[0176] Compared with the Zhuang medicine group, the positive control group still had a small amount of inflammatory cell infiltration and a thicker epidermis.

[0177] This indicates that both prednisolone acetate tablets and Zhuang medicine Shidu Xiaotang can effectively improve the structure of skin lesions in mice, and the effect of Zhuang medicine Shidu Xiaotang is better than that of prednisolone acetate tablets.

[0178] Third, comparative study

[0179] 1. Observational subject:

[0180] 120 patients with acute eczema were selected and divided into four groups. There were no significant differences in age, gender, weight, and disease severity among the four groups (all P>0.05).

[0181] 2. Medication and observation results

[0182] Control Group 1: The preparation method of this example is basically the same as that of Example 2, except that the raw materials of the first composition and the second composition are the same.

[0183] The first composition lacks the following ingredients: *Symplocos buergeriana*, *Abrus precatorius*, and *Trichosanthes kirilowii*.

[0184] The second composition lacks the following ingredients: dried plum, schisandra fruit, five-finger peach, and honeysuckle vine.

[0185] Control group 2: The preparation method of this example is basically the same as that of example 2, except that there is no second composition.

[0186] Control group 3: The preparation method of this embodiment is basically the same as that of Example 2, except that the raw materials of the first composition are different.

[0187] The first composition lacks the following ingredients: *Symplocos buergeriana*, *Hemiberlesia lingua*, and *Trichosanthes kirilowii*.

[0188] Treatment group: Example 2 was used;

[0189] All four groups were treated for 14 days as one course of treatment. The therapeutic effect was observed after the course of treatment, as detailed in Table 10.

[0190] Table 10 Comparison of treatment efficacy among the four groups

[0191]

[0192]

[0193] The table above shows that the clinical efficacy of the treatment group was 85.18%, the efficacy of control group 1 was 58.62%, the efficacy of control group 2 was 64.28%, and the efficacy of control group 3 was 67.85%. The difference is statistically significant, indicating that the Zhuang medicine Shidu Xiaotang in the treatment group is superior to control group 1 and control group 2 in terms of efficacy. In this application, the selection of raw materials is very important. If one or more raw materials are missing, the therapeutic effect will be significantly reduced.

[0194] The foregoing description of specific exemplary embodiments of the invention is for illustrative and explanatory purposes. These descriptions are not intended to limit the invention to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the foregoing teachings. The exemplary embodiments were chosen and described in order to explain the specific principles of the invention and its practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the invention, as well as various different choices and variations. The scope of the invention is intended to be defined by the claims and their equivalents.

Claims

1. A Zhuang medicine formula for treating eczema, characterized in that, Made from a first composition and a second composition, wherein, The raw materials of the first composition are Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala, and Saposhnikovia divaricata; by weight, Smilax glabra 20-40 parts, Polygonum aviculare 6-15 parts, Abrus precatorius 20-40 parts, Trichosanthes kirilowii 6-15 parts, Atractylodes macrocephala 6-15 parts, and Saposhnikovia divaricata 6-15 parts. The raw materials of the second composition are Dictamnus dasycarpus root bark, Lonicera japonica vine, Lithospermum erythrorhizon root, Prunus mume, Stellaria dichotoma root, Schisandra chinensis fruit, Ficus hirta fruit, Portulaca oleracea fruit, Glycyrrhiza uralensis root, Astragalus membranaceus root, and Artemisia capillaris fruit. By weight, Dictamnus dasycarpus root bark 15-30 parts, Lonicera japonica vine 10-20 parts, Lithospermum erythrorhizon root 5-15 parts, Prunus mume fruit 15-30 parts, Stellaria dichotoma root 5-15 parts, Schisandra chinensis fruit 5-15 parts, Ficus hirta fruit 15-30 parts, Portulaca oleracea fruit 5-15 parts, Glycyrrhiza uralensis root 4-8 parts, Astragalus membranaceus root 20-30 parts, and Artemisia capillaris fruit 10-20 parts.

2. The Zhuang medicine formula for treating eczema, Shidu Xiaotang, as described in claim 1, is characterized in that... By weight, the first composition consists of 30 parts of Smilax glabra, 10 parts of Polygonum aviculare, 30 parts of Abrus precatorius, 10 parts of Scutellaria baicalensis, 10 parts of Atractylodes macrocephala, and 10 parts of Saposhnikovia divaricata.

3. The Zhuang medicine formula for treating eczema, Shidu Xiaotang, as described in claim 1, is characterized in that... By weight, the raw materials of the second composition consist of 20 parts of Dictamnus dasycarpus root bark, 15 parts of Lonicera japonica vine, 10 parts of Lithospermum erythrorhizon root, 20 parts of Prunus mume, 10 parts of Stellaria dichotoma root, 10 parts of Schisandra chinensis fruit, 20 parts of Ficus hirta fruit, 10 parts of Portulaca oleracea fruit, 6 parts of Glycyrrhiza uralensis root, 25 parts of Astragalus membranaceus root, and 15 parts of Artemisia capillaris fruit.

4. A method for preparing a Zhuang medicine formula for treating eczema, as described in any one of claims 1-3, characterized in that, Includes the following steps: (1) Weigh the raw materials of the first composition according to the weight parts, and wash and dry the Smilax glabra, Polygonum aviculare, Abrus precatorius, Trichosanthes kirilowii, Atractylodes macrocephala and Saposhnikovia divaricata separately. (2) Weigh the raw materials of the second composition according to the weight parts, and rinse and dry the following herbs separately: Dictamnus dasycarpus root bark, Lonicera japonica vine, Lithospermum erythrorhizon root, Prunus mume, Stellaria dichotoma root, Schisandra chinensis fruit, Ficus hirta fruit, Portulaca oleracea root, Glycyrrhiza uralensis root, Astragalus membranaceus root, and Artemisia capillaris root; and set aside. (3) Add 3-5 times the amount of water to the first and second compositions, simmer over low heat to concentrate and then package.

5. The preparation method of the Zhuang medicine Shidu Xiaotang for treating eczema according to claim 4, characterized in that, In step (3), each bag contains 200ml~300ml.

Images